Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Summary
Alport syndrome (AS) is the second most common monogenic cause of end-stage renal failure (ESRF). AS is caused by variants in the COL4A3, COL4A4, and COL4A5 genes, which encode for the a3, a4, and a5 chains of type IV collagen. This trial is a prospective, randomized, controlled and multicenter trial. Mainly to assess the safety and efficacy of ramipril in Alport syndrome patients with variants of COL4A3/COL4A4/COL4A5.
Official title: Safety and Efficacy of Early Angiotensin-converting Enzyme Inhibition in Patients With Alport Syndrome Carrying Pathogenic Heterozygous COL4A3,COL4A4 or COL4A5 Mutations
Key Details
Gender
All
Age Range
30 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
510
Start Date
2022-01-01
Completion Date
2026-12-31
Last Updated
2021-11-24
Healthy Volunteers
No
Conditions
Interventions
Ramipril
We use ACEI: ramipril, in this prospective, randomized, controlled and multicenter clinical trial to access the safety and efficacy in Alport syndrome patients carried COL4A3/COL4A4/COL4A5 variants.
Locations (1)
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China